Medicover B MEDI.SE | STOCKHOLM Exch | Medical-Services | MktCap SEK19.26B Sales SEK24.79B | Shares 74M Float 52M | EPS Due in 22 Days (e)

46840017600 medicover.com Stockholm, SWEDEN Inc 2016 MGMT owns --

EPS Rank 61

Medicover AB engages in the provision of invitro diagnostics and healthcare services. It operates through the Healthcare Services and Diagnostic Services segments. The Healthcare Services segment includes the provision of employer funded healthcare services for employees and sometimes their families. The Diagnostic Services segment offers a broad range of routine and advanced laboratory testing across all clinical pathology areas. The company was founded in 1995 and is headquartered in Stockholm, Sweden. LESS

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS SEK	0.31	1.51	1.72	1.79	1.91	6.96	0.84	1.35	1.27
CASH FLOW/SHR SEK	1.51	3.67	5.12	5.96	10.47	13.54	9.97	12.46	15.85
PRETAX MARGIN %	3%	5%	5%	4%	4%	10%	1%	1%	1%
RETURN ON EQUITY %	5%	9%	8%	7%	7%	21%	2%	4%	4%
SALES % CHANGE	21%	19%	23%	30%	17%	33%	15%	25%	19%
SALES (MIL) SEK	4,710	5,591	6,894	8,941	10K	14K	16K	20K	24K

WEEKLY	May 9	May 16	May 23	May 30	Jun 6	Jun 13	Jun 20	Jun 27	Jul 1
DATAGRAPH RATING	72	77	70	72	71	73	70	75	75
AVG DAILY VOL (000)	74	82	81	82	84	94	94	105	107
UP DOWN VOLUME	1.6	2.0	2.3	2.0	2.4	2.6	2.5	3.6	3.4
ACCUM/DIST RATING	28	41	34	40	38	30	31	42	47
RELATIVE STRENGTH	86	88	84	84	82	83	79	85	86
GROUP RANK	46	49	54	45	45	40	54	33	32

2025 Estimate	2026 Estimate
5.89 364%	8.13 38%

Earnings Growth Rate	Sales Growth Rate
2023-25 -16% (77 Stability)	20%
2021-25 -4% (99 Stability)	23%

COMP RATING 97 SMR RATING B

INV T/O 26.7x 88

DEBT %	2022-24	172%	153%	205%
TAX RATE	2022-24	30%	22%	27%
BACKLOG	2022-24	--	--	--

R & D -- BK VAL 7.16x '24

DIV SEK 4.26 (1.7%) DIV GR RT+22% (16)

BETA 0.62(12.00) ALPHA 0.13 (0.07)

2024 EMPLOYEES 47,256 (4%)

+ 4% from Pivot in 2 Weeks

Developed Long +10.92% in 9 WKS

OH 0% LOG (Fixed) PRICE

The stock is forming the right side of a stage-one five-week flat base with a pivot of SEK 250. Immediate support is at its 21-DMA (SEK 242.91)

EPS Rank expected to improve given the 2025 and 2026 earnings growth estimates

Excellent fundamental profile, with triple- and double-digit earnings growth estimates for 2025 and 2026

Strong technical profile

RS line is trending upward, with an RS Rating of 86 and an Acc/Dist Rating of A



FINANCIALS	Sep 20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25
EPS (SEK)	1.12	1.26	1.76	2.06	1.26	1.88				0.84	0.11	0.42	-0.08	0.89	0.47	0.48	-0.34	0.66	1.50	1.27e
EPS % CHANGE			+3K%	+449%	+12%	+49%									+327%	+14%	-325%	-26%	+219%	+165%e
SALES (MIL SEK)	2,720.7	3,056.4	3,210.4	3,538.6	3,414.7	3,811.9				16,062.1	4,696.6	4,872.4	5,181.0	5,299.2	5,627.9	5,862.1	6,042.9	6,391.3	6,494.3	6,673.4e
SALES % CHANGE			+26%	+67%	+26%	+25%									+20%	+20%	+17%	+21%	+15%	+14%e
EPS % SURPRISE	+116.0%	+36.7%	-13.0%	-24.8%	-37.9%	-472.0%				-90.7%	-94.3%	-79.0%	-114.0%	+178.6%	+36.7%	-30.0%	-142.9%	+41.5%	+49.4%	
FUNDS	64	70	101	111	108	115	115	104	101	132	142	145	144	164	176	194	198	200	198	
SHARES HELD BY FUNDS	18M	20M	23M	24M	24M	25M	25M	24M	24M	25M	23M	23M	23M	22M	22M	22M	22M	23M	23M	

P/E	110
2025 Est.:	44.1
2026 Est.:	32.0
5-yr High:	417
5-yr Low:	29
vs Ind. Avg:	0.4x

PANARAY® 2025 WILLIAM O'NEIL + CO. INC.